Solventum (NYSE:SOLV) Downgraded to “Hold” Rating by Zacks Research

Solventum (NYSE:SOLV) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Monday,Zacks.com reports.

Other equities research analysts have also issued research reports about the company. Piper Sandler upped their price objective on Solventum from $94.00 to $98.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Weiss Ratings reissued a “hold (c)” rating on shares of Solventum in a research note on Thursday, October 30th. Wells Fargo & Company boosted their target price on Solventum from $79.00 to $82.00 and gave the stock an “equal weight” rating in a report on Monday, September 15th. BTIG Research raised shares of Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a report on Tuesday. Finally, UBS Group reissued a “neutral” rating on shares of Solventum in a research note on Friday, November 21st. Four analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $87.00.

Solventum Stock Performance

Shares of SOLV stock opened at $85.61 on Monday. Solventum has a 1 year low of $60.70 and a 1 year high of $88.20. The firm has a market capitalization of $14.85 billion, a price-to-earnings ratio of 9.86, a price-to-earnings-growth ratio of 9.03 and a beta of 0.26. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. The business has a fifty day moving average of $74.25 and a 200 day moving average of $73.83.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The company had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.05 billion. During the same quarter in the prior year, the company earned $1.64 EPS. Solventum’s quarterly revenue was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. As a group, research analysts expect that Solventum will post 6.58 earnings per share for the current year.

Solventum announced that its board has authorized a share repurchase program on Thursday, November 20th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 7.5% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s management believes its shares are undervalued.

Institutional Investors Weigh In On Solventum

Several large investors have recently bought and sold shares of the stock. Strengthening Families & Communities LLC boosted its stake in shares of Solventum by 376.8% in the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock valued at $25,000 after buying an additional 260 shares during the period. Measured Wealth Private Client Group LLC acquired a new stake in Solventum during the third quarter worth approximately $25,000. Deseret Mutual Benefit Administrators raised its stake in Solventum by 78.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after acquiring an additional 163 shares in the last quarter. CYBER HORNET ETFs LLC purchased a new stake in shares of Solventum in the 2nd quarter valued at about $28,000. Finally, Barrett & Company Inc. boosted its holdings in shares of Solventum by 206.2% in the second quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock valued at $30,000 after acquiring an additional 268 shares during the period.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.